Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), a pioneer in innovative cancer therapies, has announced that CFO Raphi Levy will present at the upcoming Sidoti Virtual Small Cap Conference, scheduled for March 18-19, 2026. The presentation will take place on March 18, from 10:00 AM to 10:30 AM ET. Following the presentation, Mr. Levy will be available for one-on-one investor meetings, providing a valuable opportunity for interested parties to gain deeper insights into the company and its cutting-edge technology.

Founded in 2016, Alpha Tau Medical is an Israeli company specializing in the research and development of Alpha DaRT®, a novel therapeutic approach aimed at treating solid tumors. The unique technology behind Alpha DaRT was initially developed by notable professors from Tel Aviv University, Itzhak Kelson and Yona Keisari. Alpha DaRT employs Diffusing Alpha-emitters Radiation Therapy, which allows for highly targeted alpha-irradiation directly to tumor sites via intratumoral delivery of radium-224 sources. As radium decays, it releases short-lived daughter isotopes that emit high-energy alpha particles, which are designed to effectively destroy cancer cells while minimizing damage to the surrounding healthy tissue.

The company’s forward-thinking approach positions it at the forefront of oncology, with potential implications for significantly improving treatment outcomes for patients with solid tumors. Alpha Tau's participation in the Sidoti conference marks an important occasion for investor engagement, as it seeks to raise awareness of its technology and explore opportunities for financial support to further its mission in cancer therapy. For further inquiries, the investor relations contact is available via email at IR@alphatau.com.

As Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) prepares to present at the Sidoti Virtual Small Cap Conference on March 18-19, 2026, investors should carefully evaluate the implications of this event for the company's stock performance. The conference offers a platform for Alpha Tau's CFO, Raphi Levy, to discuss the company's innovative alpha-radiation therapy, Alpha DaRT, which targets solid tumors with precision while minimizing damage to surrounding healthy tissue.

The uniqueness of Alpha DaRT lies in its mechanism of action; utilizing alpha-emitters for intratumoral delivery sets it apart in the competitive oncology market. However, the commercialization of any cutting-edge therapy hinges on clinical validation and regulatory approvals. Investors should note that while early studies may have shown promise, the pathway to successful market entry can be lengthy and fraught with challenges. Thus, any updates regarding clinical trials or partnerships during the conference could be pivotal.

Potential investors should also consider market sentiment surrounding small-cap biotech firms, which are often characterized by volatility. The interest generated from participation in conferences like Sidoti can spur trading activity, but this may lead to short-term fluctuations rather than sustained growth, especially if analytical performance metrics or feedback do not meet investor expectations.

Investors are encouraged to engage in one-on-one meetings during the conference to gain insights into the management's outlook and future plans. This interaction could provide valuable context that isn't accessible through typical press releases or filings. As such, while Alpha Tau presents intriguing long-term potential, particularly if Alpha DaRT gains traction in clinical settings, market watchers should remain vigilant of the inherent risks associated with investing in developmental-stage biotech firms. Consider diversifying your portfolio to mitigate exposure as you evaluate Alpha Tau's trajectory post-conference.